133747-57-6

Basic information

• Product Name: 5-OXO-1-P-TOLYL-PYRROLIDINE-3-CARBOXYLIC ACID
• Synonyms: IFLAB-BB F1799-0544;5-OXO-1-(4-TOLYL)PYRROLIDINE-3-CARBOXYLIC ACID;5-OXO-1-P-TOLYL-PYRROLIDINE-3-CARBOXYLIC ACID;AKOS BB-6984;1-(4-METHYLPHENYL)-5-OXO-3-PYRROLIDINECARBOXYLIC ACID;1-(4-METHYLPHENYL)-5-OXOPYRROLIDINE-3-CARBOXYLIC ACID;3-pyrrolidinecarboxylic acid, 1-(4-methylphenyl)-5-oxo-;1-(4-methylphenyl)-5-oxopyrrolidine-3-carboxylic acid(SALTDATA: FREE)
• CAS NO: 133747-57-6
• Molecular Formula: C₁₂H₁₃NO₃
• Molecular Weight: 219.24
• Mol File: 133747-57-6.mol

Chemical Properties

• Melting Point: 187-188 °C
• Boiling Point: 518.5 °C at 760 mmHg
• Flash Point: 267.4 °C
• Appearance: /
• Density: 1.297g/cm³
• Vapor Pressure: 1.41E-11mmHg at 25°C
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.45±0.20(Predicted)
• CAS DataBase Reference: 5-OXO-1-P-TOLYL-PYRROLIDINE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-OXO-1-P-TOLYL-PYRROLIDINE-3-CARBOXYLIC ACID(133747-57-6)
• EPA Substance Registry System: 5-OXO-1-P-TOLYL-PYRROLIDINE-3-CARBOXYLIC ACID(133747-57-6)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 133747-57-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
5-OXO-1-P-TOLYL-PYRROLIDINE-3-CARBOXYLIC ACID is used as a key intermediate in the synthesis of various pharmaceutical drugs and research compounds. Its unique chemical structure allows for the development of novel therapeutic agents with potential applications in treating a wide range of diseases and conditions.
Used in Organic Synthesis:
In the field of organic synthesis, 5-OXO-1-P-TOLYL-PYRROLIDINE-3-CARBOXYLIC ACID is utilized as a valuable building block for the creation of complex organic molecules. Its presence of a tolyl group and carboxylic acid functionality enables the formation of diverse chemical entities, contributing to the advancement of organic chemistry.
Used in Drug Development:
5-OXO-1-P-TOLYL-PYRROLIDINE-3-CARBOXYLIC ACID is employed as a precursor in the development of new drugs, offering a foundation for the design and synthesis of innovative therapeutic agents. Its potential applications in drug development highlight its importance in the pharmaceutical industry, as it can contribute to the discovery of novel treatments for various medical conditions.
Used in Medicinal Chemistry:
In medicinal chemistry, 5-OXO-1-P-TOLYL-PYRROLIDINE-3-CARBOXYLIC ACID is utilized as a structural component in the design of bioactive molecules. Its unique features, such as the tolyl group and carboxylic acid functionality, provide opportunities for the creation of compounds with specific biological activities, making it a valuable asset in the development of new pharmaceutical agents.
Overall, 5-OXO-1-P-TOLYL-PYRROLIDINE-3-CARBOXYLIC ACID is a versatile chemical compound with significant applications in various fields, including pharmaceutical research, organic synthesis, drug development, and medicinal chemistry. Its unique structure and functional groups make it a promising building block for the creation of novel therapeutic agents and the advancement of scientific knowledge.

InChI:InChI=1/C12H13NO3/c1-8-2-4-10(5-3-8)13-7-9(12(15)16)6-11(13)14/h2-5,9H,6-7H2,1H3,(H,15,16)/p-1/t9-/m1/s1

Upstream product

• 97-65-4 2-methylenesuccinic acid 
• 106-49-0 p-toluidine 

Downstream Products

• 133747-58-7 methyl 5-oxo-1-(p-tolyl)pyrrolidine-3-carboxylate 
• 848317-65-7 [N-(4-methylphenyl)pyrrolidin-3-yl]methanol 
• 133747-59-8 1-(4-Tolyl)-4-hydroxymethyl-2-pyrrolidone 
• 133747-61-2 Methanesulfonic acid 5-oxo-1-p-tolyl-pyrrolidin-3-ylmethyl ester 
• 133747-60-1 Methyl 4-[1-(4-tolyl)-2-pyrrolidon-4-yl]methoxybenzoate 
• 946243-50-1 C₁₉H₁₆ClN₃O₂ 
• 946307-06-8 C₁₉H₁₇N₃O₂ 
• 946276-49-9 C₂₀H₁₉N₃O₂ 
• 946276-53-5 C₁₉H₁₆FN₃O₂ 
• 946376-22-3 C₂₀H₁₉N₃O₃ 

Relevant articles and documents

Pyrrolidin-2-one linked benzofused heterocycles as novel small molecule monoacylglycerol lipase inhibitors and antinociceptive agents

Eighteen pyrrolidin-2-one linked benzothiazole, and benzimidazole derivatives (10–27) were designed and synthesized. The structure of the compounds was confirmed by elemental and spectral (IR, 1H-NMR and MS) data analysis. All the compounds wer

Synthesis of a novel and potent small-molecule antagonist of PAC1 receptor for the treatment of neuropathic pain

We recently identified novel small-molecule antagonists of the PACAP type I (PAC1) receptor using docking-based in silico screening followed by in vitro/vivo pharmacological assays. In the present study, we synthesized 18 novel derivatives based on the structure of PA-9, a recently developed antagonist of the PAC1 receptor, with a view to obtain a panel of compounds with more potent antagonistic and analgesic activities. Among them, compound 3d showed improved antagonistic activities. Intrathecal injection of 3d inhibited both pituitary adenylate cyclase-activating polypeptide (PACAP) and spinal nerve ligation-induced mechanical allodynia. The effects were more potent than PA-9. Compound 3d also showed anti-allodynic effects following oral administration. Hence, our results suggest that 3d may become an orally available analgesic in the treatment of the neuropathic pain.

Analgesic and anticancer activity of benzoxazole clubbed 2-pyrrolidinones as novel inhibitors of monoacylglycerol lipase

Ten benzoxazole clubbed 2-pyrrolidinones (11–20) as human monoacylglycerol lipase inhibitors were designed on the criteria fulfilling the structural requirements and on the basis of previously reported inhibitors. The designed, synthesized, and characterized compounds (11–20) were screened against monoacylglycerol lipase (MAGL) in order to find potential inhibitors. Compounds 19 (4-NO2 derivative) and 20 (4-SO2 NH2 derivative), with an IC50 value of 8.4 and 7.6 nM, were found most active, respectively. Both of them showed micromolar potency (IC50 value above 50 μM) against a close analogue, fatty acid amide hydrolase (FAAH), therefore considered as selective inhibitors of MAGL. Molecular docking studies of compounds 19 and 20 revealed that carbonyl of 2-pyrrolidinone moiety sited at the oxyanion hole of catalytic site of the enzyme stabilized with three hydrogen bonds (~2 ?) with Ala51, Met123, and Ser122, the amino acid residues responsible for the catalytic function of the enzyme. Remarkably, the physiochemical and pharmacokinetic properties of compounds 19 and 20, computed by QikProp, were found to be in the qualifying range as per the proposed guideline for good orally bioactive CNS drugs. In formalin-induced nociception test, compound 20 reduced the pain response in acute and late stages in a dose-dependent manner. They significantly demonstrated the reduction in pain response, having better potency than the positive control gabapentin (GBP), at 30 mg/kg dose. Compounds 19 and 20 were submitted to NCI, USA, for anticancer activity screening. Compounds 19 (NSC: 778839) and 20 (NSC: 778842) were found to have good anticancer activity on SNB-75 cell line of CNS cancer, exhibiting 35.49 and 31.88% growth inhibition (% GI), respectively.

A2Badenosine receptor antagonists: Design, synthesis and biological evaluation of novel xanthine derivatives

A2BAdoR is a low affinity adenosine receptor that functions by Gs mediated elevation of cAMP and subsequent downstream signaling. The receptor has been implicated in lung inflammatory disorders like?COPD and asthma. Several potent and selective

PYRROLIDONE DERIVATIVES, OLIGOMERS AND POLYMERS

Simple organic structures, organic/inorganic polymers, and other substrates have been made, all of which have at least one pyrrolidone moiety present, and found to exhibit low toxicity, low complement activation features and may be used to reduce protein

AUTOTAXIN INHIBITORS

The present invention relates to compounds of formula (I): wherein R1, R2, R3, R4a, R4b, R4C, R4d, L, A, Q, W and HET are each as defined herein. The compounds of the present inv

N-Aryl pyrrolidinonyl oxadiazoles as potent mGluR5 positive allosteric modulators

A novel series of N-aryl pyrrolidinonyl oxadiazoles were identified as mGluR5 positive allosteric modulators (PAMs). Optimization of the initial lead compound 6a led to the identification of the 12c (-) enantiomer as a potent compound with acceptable in vitro clearance, CYP, hERG and PK properties. Para substituted N-aryl pyrrolidinonyl oxadiazoles are mGluR5 PAMs while the meta and ortho substituted N-aryl pyrrolidinonyl oxadiazoles are negative allosteric modulators (NAMs). Para fluoro substitution on the N-aryl group and meta chloro or methyl substituents on the aryl oxadiazole moiety are optimal for mGluR5 PAM efficacy. The existence of an exquisitely sensitive 'PAM to NAM switch' within this chemotype making it challenging for simultaneous optimization of potency and drug-like properties.

Polycyclic systems containing 1,2,4-oxadiazole ring 2*. 4-(1,2,4-Oxadiazol-5-YL)pyrrolidin-2-ones: Synthesis and prediction of biological activity

A one-pot condensation of 5-oxopyrrolidine-3-carboxylic acids, carbonyldiimidazole, and benzamidoximes leads to the formation of the novel 4-(1,2,4-oxadiazol-5-yl)pyrrolidin-2-one bicyclic systems, the structures of which have been confirmed by IR and su

Sodium borohydride-iodine mediated reduction of γ-lactam carboxylic acids followed by DDQ mediated oxidative aromatisation: a simple approach towards N-aryl-formylpyrroles and 1,3-diaryl-formylpyrroles

A simple methodology for the conversion of substituted N-aryl-γ-lactam 2/3-carboxylic acids to substituted N-aryl-2/3-formyl-pyrroles has been developed. Several N-aryl-γ-lactam 2/3-carboxylic acids were reduced to substituted (N-aryl-pyrroliden-2/3-yl)-m

Synthesis of 4-methyloxybenzoic acids and related compounds, and their inhibitory capacities toward fatty-acid and sterol biosynthesis

The synthesis of a series of 4-methyloxybenzoic acids and related compounds, and their evaluation for inhibitory capacity toward fatty-acid and sterol biosyntheses using rats' liver slices in vitro and rabbits